Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 40 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 53%

Law Law Headlines News

Law Law Latest News,Law Law Headlines

In updated phase 1 trial interim results of GD2-specific CAR-NKT cells in patients w/ Neuroblastoma, no dose-limiting toxicities were observed; the MTD was not reached; & there was evidence of anti-tumor activity. HeczeyLab BCMFromtheLabs

The authors are grateful to M. Brenner, H. Heslop and personnel of the cGMP facility at the Center for Cell and Gene Therapy for manufacturing CAR-NKTs, including A. Jacques, J. Sritabal-Ramirez, H. Hu, K. Matzar and R. Al Hussien. We also thank K. Kukreja of the Interventional Radiology section and P.

Andras Heczey, Xin Xu, Amy N. Courtney, Gengwen Tian, Gabriel A. Barragan, Linjie Guo, Claudia Martinez Amador, Nisha Ghatwai, Purva Rathi, Michael S. Wood, Yanchuan Li, Chunchao Zhang, Thorsten Demberg, Erica J. Di Pierro & Leonid S. Metelitsa Department of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USADepartment of Radiology, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, USABiostatistics and Data Management Resource, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USABrian D. WeissAntonino Montalbano, Meena Subramaniam, Chenling Xu, Chirag Sachar & Daniel K.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in LAW

Law Law Latest News, Law Law Headlines